Matthew R. Smith, MD, PhD - Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individuali

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Go online to PeerView.com/UDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for metastatic castration-sensitive prostate cancer (mCSPC) has evolved rapidly in recent years, and research endeavors continue to expand treatment options with significant implications for patients. In addition to the approval of multiple second-generation androgen deprivation therapies (ADTs), current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. Furthermore, when managing patients with mCSPC, clinicians must consider established, newly approved, and emerging therapies, as well as individual patient-, tumor-, and treatment-related factors. Given the wealth of new options, how do clinicians determine the best treatment course for each patient? Answers to this and other thought-provoking queries are provided in this educational activity based on a recent live symposium, as a panel of prostate cancer experts examine the latest clinical data for novel and emerging therapeutic approaches and discuss evidence-based strategies for individualizing treatment for each patient with mCSPC. Upon completion of this activity, participants should be better able to: Assess the rationale and clinical evidence for novel therapeutic approaches for patients with mCSPC, such as the addition of novel androgen axis inhibitors or docetaxel to ADT, Develop optimal, individualized treatment plans for patients with mCSPC that incorporate novel therapeutics as appropriate, taking into consideration individual patient-, disease-, and treatment-related factors, Apply evidence- and team-based strategies to proactively mitigate and manage treatment-related adverse events that may occur in patients with mCSPC who are receiving novel therapeutics as part of their care, Employ effective strategies to engage patients with mCSPC in shared decision-making, with the goal of maximizing patient satisfaction, clinical outcomes, and treatment adherence.